Immatics
72 articles about Immatics
-
immatics biotechnologies GmbH Raises EUR54 Million ($71 Million) to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
9/21/2010
-
Scancell Enters Research Collaboration With immatics biotechnologies GmbH To Develop Novel Immunobody(R) Vaccines For Colorectal Cancer
6/29/2010
-
immatics biotechnologies GmbH Significantly Improves XPRESIDENT(TM) Technology Platform
6/17/2009
-
immatics biotechnologies GmbH Completes Patient Recruitment In Phase II Study With Cancer Vaccine IMA901 For Renal Cell Cancer
3/3/2009
-
immatics biotechnologies GmbH Wins 29th German Industry's Innovation Award
1/26/2009
-
immatics biotechnologies GmbH Obtains Important U.S. and European Patents
7/14/2008
-
immatics biotechnologies GmbH Appoints Paul G. Higham as Chief Executive Officer
7/9/2008
-
immatics biotechnologies GmbH Receives 3 Research Grants Totaling 1.4 mn € to Advance its Early-Stage Cancer Immunotherapy Programs
7/7/2008
-
immatics biotechnologies GmbH Granted Orphan Drug Status for Therapeutic Cancer Vaccine IMA901
3/14/2007
-
immatics biotechnologies GmbH Receives 40 Million Eur In Second Round Of Cancer Treatment Funding
2/8/2007
-
immatics biotechnologies GmbH Succesfully Concludes Phase 1 Clinical Study On Potential Renal Cell Cancer Vaccine
10/10/2006
-
immatics biotechnologies GmbH And responsif GmbH Sign A Cooperation Agreement Within The Scope Of The BioChancePLUS Grant Program
5/22/2006